Celcuity Inc. (CELC)

NASDAQ: CELC · IEX Real-Time Price · USD
5.66
0.31 (5.79%)
May 16, 2022 4:00 PM EDT - Market closed
Market Cap84.45M
Revenue (ttm)n/a
Net Income (ttm)-29.61M
Shares Out14.92M
EPS (ttm)-2.21
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume309,342
Open5.45
Previous Close5.35
Day's Range5.41 - 6.00
52-Week Range5.31 - 33.01
Beta1.52
AnalystsBuy
Price Target42.33 (+647.9%)
Earnings DateMay 16, 2022

About CELC

Celcuity Inc., a clinical stage biotechnology company, focuses on the development of molecularly targeted therapies for cancer patients in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment. Its drug candidate includes Gedatolisib, which selectively targets various class I isoforms of PI3K and mammalian target of rapamycin and focus on the treatment of patients with horm...

IndustryBiotechnology
IPO DateSep 20, 2017
Employees39
Stock ExchangeNASDAQ
Ticker SymbolCELC
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 11 analysts, the average rating for CELC stock is "Buy." The 12-month stock price forecast is 42.33, which is an increase of 647.88% from the latest price.

Price Target
$42.33
(647.88% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Celcuity Inc. Reports First Quarter 2022 Financial Results and Business Updates

Entered into $100 Million Private Placement Agreement Finalized pivotal Phase 3 trial design for gedatolisib Received FDA Fast Track designation for gedatolisib in HR+/HER2- advanced breast cancer Manag...

7 hours ago - Accesswire

Celcuity Inc. Announces $100 Million Private Placement

Proceeds to Advance Clinical Development of Gedatolisib Including Forthcoming Phase 3 Clinical Study (VIKTORIA-1) MINNEAPOLIS, MN / ACCESSWIRE / May 16, 2022 / Celcuity Inc. (Nasdaq:CELC), a clinical-st...

16 hours ago - Accesswire

Celcuity Inc. Schedules Release of First Quarter 2022 Financial Results and Webcast/Conference Call

MINNEAPOLIS, MN / ACCESSWIRE / May 9, 2022 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing an integrated therapeutic and companion diagnostic strategy for treating patient...

1 week ago - Accesswire

Celcuity to Participate in Upcoming Needham and Canaccord Genuity Investor Conferences

MINNEAPOLIS, MN / ACCESSWIRE / April 5, 2022 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing an integrated therapeutic and companion diagnostic strategy for treating patie...

1 month ago - Accesswire

Celcuity Inc. Reports Fourth Quarter and Full Year 2021 Financial Results, Pivotal Phase 3 Trial Design for Gedatolis...

Finalized pivotal Phase 3 trial design following formal meetings with FDA Received FDA Fast Track designation for gedatolisib in HR+/HER2- metastatic breast cancer Presented updated Phase 1b data during...

1 month ago - Accesswire

Celcuity Inc. Schedules Release of Fourth Quarter and Full Year 2021 Financial Results and Webcast/Conference Call

MINNEAPOLIS, MN / ACCESSWIRE / March 16, 2022 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing an integrated therapeutic and companion diagnostic strategy for treating pati...

2 months ago - Accesswire

Celcuity to Participate in the Cowen 42nd Annual Health Care Conference

MINNEAPOLIS, MN / ACCESSWIRE / March 2, 2022 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing an integrated therapeutic and companion diagnostic strategy for treating patie...

2 months ago - Accesswire

Celcuity Receives FDA Fast Track Designation for Gedatolisib in HR+ / HER2- Metastatic Breast Cancer and Provides Cor...

FDA's Fast Track Designation for the pan-PI3K/mTOR inhibitor highlights potential to address the urgent need for new treatment options for breast cancer patients On track to finalize Phase 3 clinical tr...

3 months ago - Accesswire

Celcuity Presents Updated Results of Phase 1b Study of Gedatolisib in Combination with Palbociclib and Endocrine Ther...

78% ORR in 3rd line patients and 63% ORR overall in patients treated with three weeks on/one week off gedatolisib dosing schedule (Arm D) MINNEAPOLIS, MN / ACCESSWIRE / December 10, 2021 / Celcuity Inc....

5 months ago - Accesswire

Celcuity to Present at the 2021 San Antonio Breast Cancer Symposium

MINNEAPOLIS, MN / ACCESSWIRE / December 2, 2021 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing an integrated therapeutic and companion diagnostic strategy for treating pa...

5 months ago - Accesswire

Celcuity Appoints Michael Snitkovsky as VP of Program Management and David Bridge as VP of Quality Assurance and Proc...

MINNEAPOLIS, MN / ACCESSWIRE / November 29, 2021 / Celcuity Inc. (Nasdaq:CELC), a clinical-stage biotechnology company pursuing an integrated therapeutic and companion diagnostic strategy for treating p...

5 months ago - Accesswire

Celcuity Announces Clinical Trial Collaboration and Supply Agreement with Pfizer to Provide Ibrance(R) (palbociclib) ...

MINNEAPOLIS, MN / ACCESSWIRE / November 15, 2021 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing an integrated therapeutic and companion diagnostic strategy for treating p...

6 months ago - Accesswire

Celcuity to Participate in Upcoming Jefferies and Craig-Hallum Investor Conferences

MINNEAPOLIS, MN / ACCESSWIRE / November 9, 2021 / Celcuity Inc. (Nasdaq:CELC), a clinical-stage biotechnology company pursuing an integrated therapeutic and companion diagnostic strategy for treating pa...

6 months ago - Accesswire

Celcuity Inc. Reports Third Quarter 2021 Financial Results and Provides Corporate Update

On track to obtain FDA feedback and initiate a Phase 3 study for gedatolisib during the first half of 2022 Will present updated Phase 1b data during a Spotlight Poster Discussion Session at the 2021 San...

6 months ago - Accesswire

Celcuity Inc. Schedules Release of Third Quarter 2021 Financial Results and Webcast/Conference Call

MINNEAPOLIS, MN / ACCESSWIRE / October 29, 2021 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing an integrated companion diagnostic and therapeutic strategy for treating pa...

6 months ago - Accesswire

Celcuity Announces Clinical Trial Collaboration with University of Rochester Wilmot Cancer Center and Puma to Study P...

MINNEAPOLIS--(BUSINESS WIRE)---- $CELC #Celcuity--Celcuity announces clinical trial collaboration with U of Rochester and Puma for Phase 2 breast cancer study. Patient selection guided by CELsignia.

6 months ago - Business Wire

Celcuity Inc. Reports Second Quarter 2021 Financial Results and Provides Corporate Update

Raised approximately $56.3 million of gross proceeds from a follow-on public offering of common stock in early July to provide funding for clinical development activities  After follow-on offering, Celc...

9 months ago - Accesswire

Celcuity to Participate in the Canaccord Genuity 41st Annual Growth Conference

MINNEAPOLIS, MN / ACCESSWIRE / August 5, 2021 / Celcuity Inc. (Nasdaq:CELC), a clinical-stage biotechnology company pursuing an integrated companion diagnostic and therapeutic strategy for treating pati...

9 months ago - Accesswire

Celcuity Inc. Schedules Release of Second Quarter 2021 Financial Results and Webcast

MINNEAPOLIS, MN / ACCESSWIRE / August 2, 2021 / Celcuity Inc. (Nasdaq:CELC), a clinical-stage biotechnology company pursuing an integrated companion diagnostic (CDx) and therapeutic strategy for treatin...

9 months ago - Accesswire

Celcuity to Participate in the William Blair Biotech Focus Conference

MINNEAPOLIS, MN / ACCESSWIRE / July 8, 2021 / Celcuity Inc. (Nasdaq:CELC), a clinical-stage biotechnology company pursuing an integrated companion diagnostic and therapeutic strategy for treating patien...

10 months ago - Accesswire

Why Celcuity Stock Is Crashing Today

The clinical-stage biotech announced the pricing of a secondary stock offering.

10 months ago - The Motley Fool

Celcuity Announces Pricing of Follow-on Offering

MINNEAPOLIS, MN / ACCESSWIRE / June 28, 2021 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing an integrated companion diagnostic and therapeutic strategy for treating patie...

10 months ago - Accesswire

Celcuity Announces Launch of Follow-on Offering

MINNEAPOLIS, MN / ACCESSWIRE / June 28, 2021 / Celcuity Inc. (Nasdaq:CELC), a clinical-stage biotechnology company pursuing an integrated companion diagnostic and therapeutic strategy for treating patie...

10 months ago - Accesswire

Celcuity Announces Appointment of Dr. Igor Gorbatchevsky as VP of Clinical Development and Jill Krause as VP of Clini...

MINNEAPOLIS, MN / ACCESSWIRE / June 9, 2021 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing an integrated companion diagnostic and therapeutic strategy for treating patien...

11 months ago - Accesswire

Celcuity Inc. Reports First Quarter 2021 Financial Results and Provides Corporate Update

Entered into worldwide licensing agreement with Pfizer to develop and commercialize gedatolisib, a first-in-class PI3K/mTOR inhibitor, in clinical development for breast cancer Announced encouraging pre...

1 year ago - Accesswire